Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HCAR3 | P49019 | 9/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3866808 | 0.87 | APEX1 (0.66) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL29140441 | 0.86 | CASP6 (0.68) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL12768130 | 0.83 | CASP6 (0.58) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL18779398 | 0.79 | MEN1 (0.74) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL29577830 | 0.78 | CASP6 (1.00) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL504055 | 0.78 | CASP6 (1.00) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL1609806 | 0.78 | CASP6 (0.66) | CASP6TSHRLMNAHCAR3POLB | |
| SCHEMBL11682676 | 0.78 | MEN1 (0.49) | TSHRHCAR3POLBMEN1KMT2A | |
| SCHEMBL264768 | 0.77 | TSHR (1.00) | CASP6TSHRLMNAHCAR3POLB | |
| SCHEMBL2935849 | 0.77 | BACE1 (0.45) | CASP6TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396508-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| CN-110300590-A | TYK2 inhibitor and application thereof | 林伯士拉克许米公司 | 2019-10-01 | — | — | CN | disclosed |
| EP-3528816-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| WO-2018075937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-8962244-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130217685-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-22 | — | — | US | disclosed |
| US-8377639-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-17 | — | — | US | disclosed |
| US-4014932-A | ANTHELMINTICS, PESTICIDES, MITICIDES, INSECTICIDES | THE UPJOHN COMPANY (US) | 1977-03-29 | — | — | US | disclosed |
| US-3931318-A | ANTHELMINTICS, PESTICIDES | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217685-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | TIA1, ZFP3, RBM3 | CASP6 3527/4885TSHR 4273/4885LMNA 2017/4885 |
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CASP6 4422/4885TSHR 1652/4885LMNA 2078/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CASP6 4422/4885TSHR 1652/4885LMNA 2078/4885 |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CASP6 4422/4885TSHR 1652/4885LMNA 2078/4885 |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | TIA1, ZFP3, RBM3 | CASP6 3527/4885TSHR 4273/4885LMNA 2017/4885 |
| US-11396508-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CASP6 4422/4885TSHR 1652/4885LMNA 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.